A differentiated multi-omics approach to testing of cancer and other complex diseases

PrognomIQ is a diagnostics company pursuing the development and commercialization of multi-omics tests for cancer and other complex diseases. There is large unmet need for improved diagnostic tests that will allow for earlier detection, treatment and recurrence monitoring of disease. PrognomIQ, a spin out company from Seer Inc., will leverage Seer’s Proteograph technology for unbiased proteomic analysis at unprecedented depth, breadth, and scale. PrognomIQ envisions combining this unique protein data with genomics and other omics data, to create a differentiated multi-omics approach to testing of health and disease.